CN101410394B - 抑制人免疫缺陷病毒的5-(羟基亚甲基和氨基亚甲基)取代的嘧啶 - Google Patents
抑制人免疫缺陷病毒的5-(羟基亚甲基和氨基亚甲基)取代的嘧啶 Download PDFInfo
- Publication number
- CN101410394B CN101410394B CN2007800110048A CN200780011004A CN101410394B CN 101410394 B CN101410394 B CN 101410394B CN 2007800110048 A CN2007800110048 A CN 2007800110048A CN 200780011004 A CN200780011004 A CN 200780011004A CN 101410394 B CN101410394 B CN 101410394B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- compound
- substituted
- het
- optional
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Abstract
Description
化合物编号 | IIIB | pSi(IIIB) | MDR | L100I+K103N | K103N+Y181C | Y181C |
1245789102161112131415222816182526 | 8.968.468.758.397.948.417.778.527.748.438.598.918.447.908.177.757.987.607.747.757.00 | 3.993.633.873.783.153.532.943.502.903.363.783.343.842.953.262.973.373.003.142792.05 | 7.096.096.456.195.796.685.186.845.485.656.086.376.275.206.335.665.805.145.666.405.12 | 8.828.468.468.077.838.376.808.587.637.738.438.867.207.158.117.517.797.207.517.856.33 | 8.498.498.247.737.328.026.128.397.077.028.148.387.417.007.747.037.187.026.977.626.24 | 8.448.078.278.077.677.846.618.427.257.618.228.447717.127757.217.707.057.107.746.66 |
化合物编号 | IIIB | pSi(IIIB) | MDR | L100I+K103N | K103N+Y181C | Y181C |
2720193031323334 | 7.708.558.648.438.528.488.627.96 | 2.783.633.613.303.573.623.823.36 | 6.275.977.155.895.826.076.815.81 | 7.848.508.827.418.048.417.626.58 | 7.548.378.447.647.707.757.506.59 | 7.708.138.407.718.067.937.867.03 |
Claims (6)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06112045 | 2006-03-30 | ||
EP06112045.7 | 2006-03-30 | ||
PCT/EP2007/053113 WO2007113256A1 (en) | 2006-03-30 | 2007-03-30 | Hiv inhibiting 5-(hydroxymethylene and aminomethylene) substituted pyrimidines |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101410394A CN101410394A (zh) | 2009-04-15 |
CN101410394B true CN101410394B (zh) | 2012-02-08 |
Family
ID=36808784
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007800110048A Active CN101410394B (zh) | 2006-03-30 | 2007-03-30 | 抑制人免疫缺陷病毒的5-(羟基亚甲基和氨基亚甲基)取代的嘧啶 |
Country Status (18)
Country | Link |
---|---|
US (1) | US8163745B2 (zh) |
EP (1) | EP2004641B1 (zh) |
JP (1) | JP5070278B2 (zh) |
KR (1) | KR20080104040A (zh) |
CN (1) | CN101410394B (zh) |
AT (1) | ATE482953T1 (zh) |
AU (1) | AU2007233739B2 (zh) |
BR (1) | BRPI0709266B8 (zh) |
CA (1) | CA2645959C (zh) |
DE (1) | DE602007009508D1 (zh) |
DK (1) | DK2004641T3 (zh) |
ES (1) | ES2353725T3 (zh) |
HR (1) | HRP20100696T1 (zh) |
IL (1) | IL193725A (zh) |
MX (1) | MX2008012577A (zh) |
RU (1) | RU2452737C2 (zh) |
SI (1) | SI2004641T1 (zh) |
WO (1) | WO2007113256A1 (zh) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2533258T3 (es) * | 2005-02-18 | 2015-04-08 | Janssen Sciences Ireland Uc | Derivados de óxido de 2-(4-cianofenilamino)pirimidina que inhiben el VIH |
CN101573343B (zh) * | 2006-12-29 | 2016-02-24 | 爱尔兰詹森科学公司 | 抑制人免疫缺陷病毒的6-取代的嘧啶 |
AU2009248923B2 (en) | 2008-05-21 | 2015-01-29 | Takeda Pharmaceutical Company Limited | Phosphorous derivatives as kinase inhibitors |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
KR20110025224A (ko) | 2008-06-27 | 2011-03-09 | 아빌라 테라퓨틱스, 인크. | 헤테로아릴 화합물 및 이의 용도 |
US11351168B1 (en) | 2008-06-27 | 2022-06-07 | Celgene Car Llc | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
EP2440559B1 (en) | 2009-05-05 | 2018-01-10 | Dana-Farber Cancer Institute, Inc. | Egfr inhibitors and methods of treating disorders |
WO2012021444A1 (en) | 2010-08-10 | 2012-02-16 | Avila Therapeutics, Inc. | Besylate salt of a btk inhibitor |
JP5956999B2 (ja) | 2010-11-01 | 2016-07-27 | セルジーン アヴィロミクス リサーチ, インコーポレイテッド | ヘテロアリール化合物およびその使用 |
NZ609957A (en) | 2010-11-01 | 2015-08-28 | Celgene Avilomics Res Inc | Heterocyclic compounds and uses thereof |
EP2637502B1 (en) | 2010-11-10 | 2018-01-10 | Celgene CAR LLC | Mutant-selective egfr inhibitors and uses thereof |
KR101884010B1 (ko) | 2011-05-04 | 2018-07-31 | 어리어드 파마슈티칼스, 인코포레이티드 | Egfr-유도된 암의 세포 증식을 억제하는 화합물 |
CN102260215A (zh) * | 2011-05-13 | 2011-11-30 | 复旦大学 | 一种二芳基嘧啶类衍生物及其制备方法和用途 |
US9364476B2 (en) | 2011-10-28 | 2016-06-14 | Celgene Avilomics Research, Inc. | Methods of treating a Bruton's Tyrosine Kinase disease or disorder |
LT2825042T (lt) | 2012-03-15 | 2018-12-10 | Celgene Car Llc | Epidermio augimo faktoriaus receptoriaus kinazės slopiklio druskos |
KR102081042B1 (ko) | 2012-03-15 | 2020-02-26 | 셀젠 카르 엘엘씨 | 상피 성장 인자 수용체 키나제 억제제의 고체 형태 |
JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Egfr発動性がんの細胞増殖阻害用化合物 |
WO2014100748A1 (en) | 2012-12-21 | 2014-06-26 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
MX2015009952A (es) | 2013-02-08 | 2015-10-05 | Celgene Avilomics Res Inc | Inhibidores de cinasas reguladas por señales extracelulares (erk) y sus usos. |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
US9492471B2 (en) | 2013-08-27 | 2016-11-15 | Celgene Avilomics Research, Inc. | Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase |
CN103483272B (zh) * | 2013-09-29 | 2015-10-21 | 山东大学 | 间二芳烃-多取代嘧啶类衍生物及其制备方法与应用 |
RU2547844C1 (ru) * | 2013-10-29 | 2015-04-10 | Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук | Способ получения 5-(гет)арил-4-(2-тиенил)-2-(тио)морфолилпиримидина |
US9415049B2 (en) | 2013-12-20 | 2016-08-16 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
TW201613892A (en) | 2014-08-13 | 2016-04-16 | Celgene Avilomics Res Inc | Forms and compositions of an ERK inhibitor |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
SK67298A3 (en) | 1995-11-23 | 1998-11-04 | Janssen Pharmaceutica Nv | Solid mixtures of cyclodextrins prepared via melt-extrusion |
SK287996B6 (sk) | 1998-03-27 | 2012-09-03 | Janssen Pharmaceutica N. V. | Pyrimide compound, pharmaceutical composition the compound is comprised, method for preparation thereof, combination and product containing the composition and use of the pyrimide compound |
HU230394B1 (hu) | 1998-11-10 | 2016-04-28 | Janssen Pharmaceutica N.V. | HIV-vírus szaporodását gátló pirimidin-származékok |
WO2001085700A2 (en) * | 2000-05-08 | 2001-11-15 | Janssen Pharmaceutica N.V. | Hiv replication inhibiting pyrimidines and triazines |
JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
WO2004065378A1 (en) * | 2003-01-17 | 2004-08-05 | Warner-Lambert Company Llc | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation |
CN102151270A (zh) * | 2003-02-07 | 2011-08-17 | 詹森药业有限公司 | 预防hiv感染的嘧啶衍生物 |
BRPI0515935B8 (pt) * | 2004-09-30 | 2021-05-25 | Janssen Sciences Ireland Uc | pirimidinas heterociclil- ou 5-carbo substituídas para inibição de hiv, e composição farmacêutica |
-
2007
- 2007-03-30 CN CN2007800110048A patent/CN101410394B/zh active Active
- 2007-03-30 EP EP07727585A patent/EP2004641B1/en active Active
- 2007-03-30 ES ES07727585T patent/ES2353725T3/es active Active
- 2007-03-30 KR KR1020087023894A patent/KR20080104040A/ko not_active Application Discontinuation
- 2007-03-30 AU AU2007233739A patent/AU2007233739B2/en not_active Ceased
- 2007-03-30 AT AT07727585T patent/ATE482953T1/de not_active IP Right Cessation
- 2007-03-30 MX MX2008012577A patent/MX2008012577A/es active IP Right Grant
- 2007-03-30 DK DK07727585.7T patent/DK2004641T3/da active
- 2007-03-30 BR BRPI0709266A patent/BRPI0709266B8/pt not_active IP Right Cessation
- 2007-03-30 CA CA2645959A patent/CA2645959C/en active Active
- 2007-03-30 RU RU2008143018/04A patent/RU2452737C2/ru active
- 2007-03-30 WO PCT/EP2007/053113 patent/WO2007113256A1/en active Application Filing
- 2007-03-30 DE DE602007009508T patent/DE602007009508D1/de active Active
- 2007-03-30 JP JP2009502114A patent/JP5070278B2/ja active Active
- 2007-03-30 SI SI200730458T patent/SI2004641T1/sl unknown
- 2007-03-30 US US12/294,725 patent/US8163745B2/en active Active
-
2008
- 2008-08-27 IL IL193725A patent/IL193725A/en active IP Right Grant
-
2010
- 2010-12-17 HR HR20100696T patent/HRP20100696T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
DE602007009508D1 (de) | 2010-11-11 |
IL193725A (en) | 2014-11-30 |
RU2008143018A (ru) | 2010-05-10 |
CA2645959A1 (en) | 2007-10-11 |
EP2004641B1 (en) | 2010-09-29 |
AU2007233739B2 (en) | 2013-01-17 |
CN101410394A (zh) | 2009-04-15 |
DK2004641T3 (da) | 2011-01-24 |
US8163745B2 (en) | 2012-04-24 |
MX2008012577A (es) | 2008-10-10 |
JP2009531395A (ja) | 2009-09-03 |
BRPI0709266A2 (pt) | 2011-06-28 |
WO2007113256A1 (en) | 2007-10-11 |
KR20080104040A (ko) | 2008-11-28 |
RU2452737C2 (ru) | 2012-06-10 |
JP5070278B2 (ja) | 2012-11-07 |
EP2004641A1 (en) | 2008-12-24 |
HRP20100696T1 (hr) | 2011-01-31 |
ES2353725T3 (es) | 2011-03-04 |
AU2007233739A1 (en) | 2007-10-11 |
IL193725A0 (en) | 2009-05-04 |
ATE482953T1 (de) | 2010-10-15 |
US20100234375A1 (en) | 2010-09-16 |
BRPI0709266B8 (pt) | 2021-05-25 |
SI2004641T1 (sl) | 2011-02-28 |
BRPI0709266B1 (pt) | 2020-09-29 |
CA2645959C (en) | 2016-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101410394B (zh) | 抑制人免疫缺陷病毒的5-(羟基亚甲基和氨基亚甲基)取代的嘧啶 | |
CN101405283B (zh) | Hiv抑制性5-酰氨基取代的嘧啶类化合物 | |
CN101573343B (zh) | 抑制人免疫缺陷病毒的6-取代的嘧啶 | |
CA2923637C (en) | Hiv inhibiting 5,6-substituted pyrimidines | |
MX2007009015A (es) | Derivados de 2-(4-cianofenilamino)pirimidina que inhibien el virus de la inmunodeficiencia humana. | |
CN101415708A (zh) | 抑制HIV的3,4-二氢-咪唑并[4,5-b]吡啶-5-酮 | |
CN101103029B (zh) | 作为抗感染剂的1,5,6-取代的-2-氧代-3-氰基-1,6a-二氮杂-四氢-荧蒽 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: IRELAND JANSSEN R + D COMPANY Free format text: FORMER OWNER: JANSSEN R + D IRELAND Effective date: 20150724 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C56 | Change in the name or address of the patentee |
Owner name: TIBOTEC PHARM LTD. Free format text: FORMER NAME: TIBOTEC NV Owner name: JANSSEN R + D IRELAND Free format text: FORMER NAME: TIBOTEC PHARM LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: The Irish Village Patentee after: JANSSEN R&D IRELAND Address before: The Irish Village Patentee before: TIBOTEC PHARMACEUTICALS Address after: The Irish Village Patentee after: TIBOTEC PHARMACEUTICALS Address before: The Irish Village Patentee before: TIBOTEC PHARMACEUTICALS Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150724 Address after: The Irish Village Patentee after: JANSSEN R&D IRELAND Address before: The Irish Village Patentee before: JANSSEN R&D IRELAND |